7mg/14mg*30 tablets

I. Indications

1.Type 2 Diabetes Mellitus (T2DM)

•As an adjunct to diet and exercise to improve glycemic control in adults.

•Cardiovascular Risk Reduction: To reduce the risk of major adverse cardiovascular events (e.g., heart attack, stroke) in adults with established cardiovascular disease and obesity/overweight.

2.Obesity/Overweight

•Adults: Body Mass Index (BMI) ≥30 kg/m² (obesity) or BMI 27–30 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes).

•Adolescents (≥12 years): BMI ≥95th percentile for age and sex.

3.Nonalcoholic Steatohepatitis (NASH)

II. Efficacy

1.Glycemic Effects

•Significantly reduces glycated hemoglobin (HbA1c), with reductions up to 1.5%.

•Mechanisms: Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying.

2.Weight Loss Effects

•Reduces appetite, decreases caloric intake, and alters preferences for high-fat foods.

3.Cardiovascular Benefits

•Reduces systolic blood pressure, mitigates inflammation, and lowers the risk of cardiovascular events.

III. Precautions

1.Contraindications

•Personal or family history of thyroid medullary carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

•Hypersensitivity to semaglutide or any excipients.

•Type 1 diabetes mellitus or diabetic ketoacidosis.

2.Special Populations

•Pregnancy/Lactation: May cause fetal harm. Discontinue at least 2 months before a planned pregnancy.

•Renal/Hepatic Impairment: Dose adjustment required in severe renal impairment; no dose adjustment needed for mild to moderate hepatic impairment.

3.Administration

•Administer orally fasting30 minutes before breakfast, with a small amount of water.

4.Storage

•Oral tablets: Store protected from light and moisture.